| Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach? M Spaas, Y Lievens Frontiers in medicine 6, 244, 2019 | 39 | 2019 |
| Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial M Spaas, N Sundahl, V Kruse, S Rottey, D De Maeseneer, F Duprez, ... JAMA oncology 9 (9), 1205-1213, 2023 | 15 | 2023 |
| Prognostic value of stimulated thyroglobulin levels at the time of radioiodine administration in differentiated thyroid cancer M Spaas, B Decallonne, A Laenen, J Billen, S Nuyts European thyroid journal 7 (4), 211-217, 2018 | 14 | 2018 |
| Clinical relevance of serum Kyn/Trp ratio and basal and IFNγ-upregulated IDO1 expression in peripheral monocytes in early stage melanoma A Meireson, L Ferdinande, M Haspeslagh, B Hennart, D Allorge, P Ost, ... Frontiers in Immunology 12, 736498, 2021 | 11 | 2021 |
| Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled … M Spaas, N Sundahl, E Hulstaert, V Kruse, S Rottey, D De Maeseneer, ... BMC cancer 21 (1), 514, 2021 | 10 | 2021 |
| Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial M Spaas, N Sundahl, S Rottey, V KRUSE, D De Maeseneer, F Duprez, ... ESTRO 2021 161 (S1), S490-S491, 2021 | 8 | 2021 |
| Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literature W Danckaert, M Spaas, K Vandecasteele, C De Wagter, P Ost Radiotherapy and Oncology 170, 64-69, 2022 | 4 | 2022 |
| Spatiotemporal evolution of radiation myositis on 18F-FDG PET/CT following hypofractionated radiotherapy of intramuscular melanoma metastases M Spaas, B Van den Broeck, D Creytens, V Kruse, P Ost Clinical Nuclear Medicine 46 (7), e384-e386, 2021 | 3 | 2021 |
| Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures A Meireson, SJ Tavernier, S Van Gassen, N Sundahl, A Demeyer, ... Cancers 13 (11), 2630, 2021 | 3 | 2021 |
| OC-0626 Toxicity of SRT combined with targeted agents: prospective analysis of the TOaSTT database S Kroeze, J Schaule, M Spaas, KH Kahl, JJ Verhoeff, FL Schneiders, ... Radiotherapy and Oncology 161, S491-S492, 2021 | 2 | 2021 |
| Microbiome and metabolome dynamics during radiotherapy for prostate cancer W Danckaert, M Spaas, N Sundahl, A De Bruycker, V Fonteyne, ... Radiotherapy and Oncology 189, 109950, 2023 | 1 | 2023 |
| PD-0064 Metastases-directed SRT combined with systemic therapy: 2y results of the TOaSTT real-world database S Kroeze, J Schaule, M Spaas, KH Kahl, JJ Verhoeff, FL Schneiders, ... Radiotherapy and Oncology 182, S31-S32, 2023 | | 2023 |
| Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial J Vanwelkenhuyzen, M Spaas, K Van der Eecken, V Kruse, S Rottey, ... OncoPoint Symposium 2022: a festive edition, 2022 | | 2022 |
| Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. M Spaas, N Sundahl, P Ost European Urology 81 (2), 216-216, 2021 | | 2021 |
| A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy M Orazem, C Draulans, M Spaas, E Van Cutsem, M Debecker, ... Clinical Journal of Gastroenterology 14, 1121-1125, 2021 | | 2021 |
| Toxicity of stereotactic Radiotherapy in Combination with targeted System Therapies: prospective Analysis of the TOaSTT Database S Kroeze, C Fritz, J Schaule, M Spaas, K Kahl, J Verhoeff, F Schneiders, ... Strahlentherapie und Onkologie 197 (SUPPL 1), S10-S10, 2021 | | 2021 |
